Skip to main content

CMML

Criteria to qualify for study: Drug used in study:
  • Must have been treated with at least 1 prior therapy.

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

An Open-Label Multicenter Phase I trial to evaluate the Safety, Pharmacokynetics and Pharmacodynamic of Splicing Modulator H3B-800 for Subjects with CMML.

Criteria to qualify for study: Drug used in study:
  • Advanced Malignancies

AML 29 BSC-101-01 Strategia Therapeutics

A Phase 1/2 study of E6201 for the treatment of advanced hematologic malignancies with FLT3 and or Ras mutations including AML, MDS or CMML.